bioshield Spekulation zum weiteren Kursverlauf - 500 Beiträge pro Seite

[defizit1]

Von Yahoo Finance - hoert sich gut an die Spekulation , aber lest selbst
mfg
defizit1So what`s BSTI worth now?
by: noiserider 10/22/00 12:11 pm
Msg: 3271 of 3278

We saw BSTI drop from a close of $7.56 on 10/10 to $1.37 on 10/19 - a loss of 80% in value. The only news released from BSTI was FDA approval. That should have moved the stock up. Part of the downward movement might be explained by general market weakness, but the market as measured by the NASDAQ actually went up. (3240 to 3418) That`s no explanation.

Maybe there was some undisclosed news that was picked up by a major astute investor who dumped their stock at firesale prices. But the company came out with a press release declaring no news. That`s no explanation.

So my speculation as mentioned before was Wilson or Jackson LLC depressing the price to get favorable terms for their series B to common conversion. If this is true and they did or will convert soon then what is the stock worth now? (continued in the next message)

Some people might say that the stock is worth less now because of dilution pointing to the 6.2M shares that possibly might be converted at the $1.61 rate mentioned in the S3 filed on 10/19. Let`s look at the dilution effect on current shareholders if all 6.2M were converted.

Let`s start with a base value on 10/10 of $7.56 for all the shares outstanding at that time. How many shares were outstanding? Many people would say 8M. Using the 8M figure the market cap or "value" of the company was $60.5M (8M x $7.56) on 10/10.

If there are now 6.2M more shares issued (after the series B conversion) then the value of the company (after everything settles down) is $60.5M/14.2M shares or $4.25 per share. This is the minimum value!! I believe the stock price will rise in the next week or so to above $4.

We`ll see in the next message that there is a reason why it is worth more.

In the last message we calculated the worth of BSTI after dilution. We used 8M as the number of shares outstanding as of 10/10, but there, IMHO, were more "effective" shares outstanding as of 10/10.

Why?

We knew as of 6/14 when the Series B agreement was signed that eventually Series B would be converted to common. We thought it would be converted at,say, maybe, $10 per share; not at $1.61. So on 10/10 most people assumed that the Series B conversion would result in 1M additional shares. Therefore the amount of "effective" outstanding shares was at least 9M (8M+1M).

In fact there were several more agreements in place that increased the number of effective shares before 10/10. There are stock options, warrants and Series B stock. I`ll ignore all but the largest. The biggest agreement is the $50M equity credit line that will be tapped to purchase AHTC for $15M and Arrow-Magnolia for $17M. At an assumed stock price of $8 per share near the announcement dates in the summer an additional 4M shares would need to be issued to Wilson LLC to get the $32M to complete the purchase. The number of "effective" shares on 10/10 was 13M (8+1+4) not 8M and the dilution effect of series B conversion is really $7.56*13M/(13M+6.2M)=$5.12. So the stock after dilution should be worth at least double what it is trading at now.

Its getting higher in value and there is one more inaccuracy that will help. On to the next message!

The S3 says that if all series B were converted at $1.61 then 6.2M shares of common would result. How many were really converted last week?

Of course we don`t know for sure that any were converted, but there is a clause in the agreement that limits the number of shares converted -at one time- to less than 4.9% of outstanding shares. That a maximum of 5%*8M or 400,000 shares. That`s far less than the 6.2M mentioned in the S3. Before more can be converted the 400,000 shares have to be sold.

Will Wilson sell those shares now? Not on your life! Why sell those shares now for $2.35 if they can be sold later for $5? No, Wilson will wait for a while; sell the shares at a higher price; then wait for an opportune moment to try the same "trick" again.

So how many more shares will Wilson be able to convert and at what price? I doubt he`ll be successful at driving the 3 day average price down to $1.61 again. First, we know what he`s doing and people will be buying way before it drops through the $3 level. Second there is a good chance that good news will be issued - either an additional FDA approval or increased revenues or more comprehensive distribution - and the stock will move about the $10 level. I`m guessing there will be in total less than 2M shares converted from the Series B stock. If so, the fair value of the stock is $7.56 * 13M/(13M+2M) = $6.55.

That`s all for now. Remember, this is all speculation. Tthe last four messages tell a story based on Wilson having driven the price down to a more favorable level to convert B to common. If we find Wilson hasn`t converted then forget everything I said.

What am I going to do? One, hold my stock bought at $1.75 for a few weeks and hope it moves above $6. Two, maybe buy a few more shares if it drops below $2 tomorrow. Three, wait for Wilson to pull the same "trick" again and short on the way down; then buy on the way up.

[Millenium-Bug]

warum postest du das nicht im Thread von zebu Muß es denn immer gleich zehn gleichlautende Threads zu einem Unternehmen geben
Hast doch vorher auch da gepostet

Bug

[defizit1]

@millenium
Entschuldige - ich wollte nur, dass mehr Leute auf diese Aktie aufmerksam werden - das errreicht man mit einem neuen Thread leichter...
Nichts für ungut.
mfg
defizit1

[Millenium-Bug]

Ok, dir sei verziehen

Finde es ja nicht schlecht, auf eine Aktie aufmerksam zu machen. Habe diese Aktie selber nicht, aber eine Antisoma als Beispiel. Und wenn ich sehe wieviele Threads da schon existieren, dann verliert man sehr schnell die Übersicht. Wünsche dir auf jeden Fall viel Glück mit Bioshield, werde sie mal beobachten, und eventuell einsteigen.

Gruß
Bug

[defizit1]

Hier eine weitere Spekulation zum Kurs von noiserider aus dem yhoo Board:
Wuerde den Kurs erklaeren. Zusaetzlich ist zu der Anfrage aus unserem anderen Thread zu sagen , dass der Kurs von 35 $ runtergegengen ist , war zuerst das allgemeine Verpruegeln von Biotech, dann hat sich der Kurs der allgemeinen Erholung nicht angeschlossen u.a. weil Wilson scheinbar ein ziemlich windiger Typ (siehe Spekulationen) ist und das Vertrauen seiner Anleger verspielt hat. Ansonsten einfach im Yahoo Board nachlesen...
mfg
defizit1

What is Wilson LLC doing?
by: noiserider 10/25/00 11:45 am
Msg: 3295 of 3297

One of my earlier messages mentioned that Wilson LLC can only hold 4.9% (400,000) of the outstanding stock at one time and that he would be unwise to sell the stock at current market prices. He would probably wait until the stock reaches a fair value of, perhaps, $8 before trying to convert more series B into common.

Here`s another less savory explanation of what`s going on.

Wilson LLC acts in concert with another investor. Let`s call her Wilma LLC, also a Cayman Island incorporated firm. Wilson converts the maximum possible (400,000) shares. Wilma enters into an agreement to purchase the 400,000 shares from Wilson at the market close for the average price. Wilson and Wilma keep the cycle going until all 6M shares are converted.

Wilma now owns 40% of the company and profits handsomely when new products are introduced, FDA approval is granted and the stock flies to $18 a share. Wilma just happens to be a friend of Wilson and shares the loot.

Is it illegal? Sure is if Wilma ever shares the gain with Wilson, but how will that be proven with Cayman Island secrecy? Otherwise, there is no law preventing conversion and sale at current prices.

I have no proof that any conversion has taken place or that there is anything nefarious going on. I just can`t logically explain the price and volume in the last week.

[eisbaer24]

Hier ein paar Nachrichten zu BioshieldBioShield Responds to Recent Market Activity
ATLANTA, Oct. 17 /PRNewswire/ -- BioShield Technologies, Inc. (Nasdaq: BSTI) today announced that the company was unaware of the reason for the recent decrease in the company`s stock price as they are unaware of any change in material events that would warrant such a decrease, said BioShield`s Chief Financial Officer, Scott Parliament.
"BioShield`s management feels the short to medium term prospects for the company are extremely positive." Mr. Parliament went on to say, "News will be forthcoming regarding events we feel reflect the positive direction of the company including discussion of the recent surge in product placement which now totals over 20,000 retail locations."
A recording of the BioShield/eMD conference call held on October 4th, 2000 is available on streetfusion.com until November 4, 2000 (www.streetfusion.com, click on Special Events on the left menu and enter the symbol BSTI).
This press release contains forward-looking information regarding BioShield Technologies, Inc. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements as to industry trends, future economic performance, anticipated profitability, anticipated revenues and expenses, anticipated transactions and closing dates for such transactions, planned product development, and products or service line growth may be significantly impacted by certain risks and uncertainties, including, but not limited to, failure of the industry to develop at anticipated rates, failure of the Companies` products and services and planned products and services to be timely developed or to gain significant market acceptance, competition and other economic factors. In addition, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," " believe," "anticipate," "intend," "could," "would," "estimate," or "continue," or the negative other variations thereof or compatible terminology are intended to identify forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Companies disclaim any intention of obligation to update these forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the Companies, including areas such as: the early-stage development of BioShield; the result of research and development efforts; future capital needs; uncertainty of additional funding; and government regulations. Additional risks and uncertainties are described in public filings of BioShield with the Securities and Exchange Commission.



2
ATLANTA, Oct. 13 /PRNewswire/ -- BioShield Technologies, Inc., (Nasdaq: BSTI) today announced that it has signed an agreement with Apollo Chemical Corporation to distribute its patented antimicrobial products, AM500 and BST1860.
The finalized agreement with Apollo Chemical represents yet another step in establishing BioShield`s chemical distribution network. Apollo Chemical is a chemical sales company with over 30 years of experience in the textile industry, and it has recently obtained the ISO 9001 certification as a Chemical manufacture & distributor.
Apollo Chemical has been in business since 1959. As a leader in chemical specialty products, it has facilities in North Carolina, Alabama, and California, and distributorships in Mexico and Australia. Apollo Chemical has an experienced and proven sales force with substantial technical support and over 1,000 clients.
"This agreement with BioShield Technologies, Inc. allows Apollo Chemical to offer an EPA registered, patented antimicrobial technology to our clients in the United States and overseas," said Ed Rish, Vice President of Apollo Chemical.
"Our clients have been asking for an antimicrobial that has residual effects, is nontoxic, and EPA registered. We are extremely pleased to be able to fill these needs using BioShield products," said Mr. Dexter R. Barbee, Jr., President of Apollo Chemical.
Tim Moses, President and CEO of BioShield stated, "We are very pleased with our agreement with Apollo Chemical, a company that is clearly a leader in the textile chemical industry. We are equally excited about their ability to provide their clients with the antimicrobial agent they`ve needed. Signing this agreement with Apollo Chemical is another example of our commitment to pursue continuous and rapid growth by providing industries with our patented, EPA registered technology. We have worked very hard. This is a very exciting time for BioShield!" Forward-Looking Statements
This press release contains forward-looking information regarding BioShield Technologies, Inc. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements as to industry trends, future economic performance, anticipated profitability, anticipated revenues and expenses, anticipated transactions and closing dates for such transactions, planned product development, and products or service line growth may be significantly impacted by certain risks and uncertainties, including, but not limited to, failure of the industry to develop at anticipated rates, failure of the Companies` products and services and planned products and services to be timely developed or to gain significant market acceptance, competition and other economic factors. In addition, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," " believe," "anticipate," "intend," "could," "would," "estimate," or "continue," or the negative other variations thereof or compatible terminology are intended to identify forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Companies disclaim any intention of obligation to update these forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the Companies, including areas such as: the early-stage development of BioShield; the result of research and development efforts; future capital needs; uncertainty of additional funding; and government regulations. Additional risks and uncertainties are described in public filings of BioShield with the Securities and Exchange Commission.



3
BioShield Technologies Receives Three EPA Registrations On First Antimicrobial Approved for Consumer use
ATLANTA, Sept. 29 /PRNewswire/ --
BioShield Technologies, Inc. (Nasdaq: BSTI) today announced that it has received three EPA registrations for consumer use of its patented antimicrobial technology. This marks the first antimicrobial approval for residential use. BioShield is currently marketing antimicrobials under six product registrations issued by the Environmental Protection Agency (EPA).
One dilutable concentrate and two ready-to-use formulations were approved on September 27, 2000 under the EPA registration numbers 70871-3 (BST Protectant Concentrate C15), 70871-4 (BST Protectant RTU 50), and 70871-5 (BST Protectant RTU 75).
"These approvals enable BioShield to enter the consumer products market with a protectant product that will revolutionize the home cleaning category" said Ted Miller, BioShield COO. "No other product in this market can compete with the long-term benefits available through BioShield`s active ingredient, which provides an invisible barrier against bacterial and fungal contamination for a time period up to three months."
Unlike other antibacterial products on the market that offer temporary protection against bacteria, BioShield offers a broader microbial protection in concert with a longer duration of protection.
The EPA registration includes approval for use on numerous surfaces, including "blankets, intimate apparel, shower curtains, air filters, carpeting, mattress pads, tents, sails, roofing materials, athletic shoes, shower stalls, sinks, kitchen appliances . . ."
This is the first product certified by the EPA that offers long-lasting protection against the contamination created by the growth of bacteria, mold, mildew and fungi in bathrooms, kitchens, and basements. In addition, the product is approved for use for various outdoor applications such as patios, outdoor furniture, awnings, siding, and boats. This broad registration will also allow consumers to apply the BioShield technology to various clothing items that are susceptible to the growth of odor-causing mildew and bacteria.
"Household cleaners serve a $2.2 billion market, said Timothy C. Moses," Chairman and CEO of BioShield Technologies. "This new breakthrough clearly demonstrates BioShield`s commitment to antimicrobial industry leadership and value creation for our shareholders".
This press release contains forward-looking information regarding BioShield Technologies, Inc. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements as to industry trends, future economic performance, anticipated profitability, anticipated revenues and expenses, anticipated transactions and closing dates for such transactions, planned product development, and products or service line growth may be significantly impacted by certain risks and uncertainties, including, but not limited to, failure of the industry to develop at anticipated rates, failure of the Companies` products and services and planned products and services to be timely developed or to gain significant market acceptance, competition and other economic factors. In addition, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," " believe," "anticipate," "intend," "could," "would," "estimate," or "continue," or the negative other variations thereof or compatible terminology are intended to identify forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Companies disclaim any intention of obligation to update these forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the Companies, including areas such as: the early-stage development of BioShield; the result of research and development efforts; future capital needs; uncertainty of additional funding; and government regulations. Additional risks and uncertainties are described in public filings of BioShield with the Securities and Exchange Commission.


BioShield Granted Significant New Patents; Two Patents Cover the Use of Technology in a Broad Range of Products
ATLANTA, Sept. 22 /PRNewswire/ -- BioShield Technologies, Inc., (Nasdaq: BSTI) today announced that it has been granted two additional patents.
BioShield has received U.S. Patent Nos. 6120587 and 6113815, which were issued by the United States Patent Office on September 19 and September 5, 2000, respectively. These additional patents disclose a method for using BioShield`s existing and previously patented antimicrobial protection process in many food, household, medical and industrial applications.
These patents present significant new opportunities for the employment of BSTI`s patented technology in areas such as:
* Antimicrobial treatment of foodstuffs, particularly perishable food
crops such as grain, fruits and vegetables

* Antimicrobial treatment of fluid containers for human or animal
consumable items, including baby products, shampoos, lotions and
toothpaste

* Improvement of consumer products such as car wax, furniture polish,
shoe polish, and leather treatments

* Incorporation of antimicrobial compounds into medical products,
including latex surgical dams and gloves as well as woven and non-woven
textile fabrics

* Industrial and commercial applications such as concrete pipe, spa and
pool filter materials, HVAC filtration applications, fiberglass as used
in modular shower stalls, roofing materials and Dryvitt and stucco
building finishes

Timothy Moses, Chairman and CEO of BSTI, stated, "These new patents, coupled with our recent EPA registrations, have placed BioShield in a leadership position in the antimicrobial industry. They are also further evidence of our commitment to research and development. We are currently awaiting additional patent approvals and EPA registrations that we believe will allow BioShield to further expand its antimicrobial products and their uses."
This press release contains forward-looking information regarding BioShield Technologies, Inc. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements as to industry trends, future economic performance, anticipated profitability, anticipated revenues and expenses, anticipated transactions and closing dates for such transactions, planned product development, and products or service line growth may be significantly impacted by certain risks and uncertainties, including, but not limited to, failure of the industry to develop at anticipated rates, failure of the Companies` products and services and planned products and services to be timely developed or to gain significant market acceptance, competition and other economic factors. In addition, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," " believe," "anticipate," "intend," "could," "would," "estimate," or "continue," or the negative other variations thereof or compatible terminology are intended to identify forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Companies disclaim any intention of obligation to update these forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the Companies, including areas such as: the early-stage development of BioShield; the result of research and development efforts; future capital needs; uncertainty of additional funding; and government regulations. Additional risks and uncertainties are described in public filings of BioShield with the Securities and Exchange Commission.


4
eMD Enters Into Strategic Alliance Partnership With Rapid Rx; eMD Invests Small Minority Equity Stake
ATLANTA, Sept. 21 /PRNewswire/ -- eMD, a business-to-business Internet healthcare subsidiary of BioShield Technologies, Inc. (Nasdaq: BSTI), today announced an agreement with Rapid Rx, which forms an important alliance between the two companies.
The alliance provides the first of its kind, in that it offers our point of care management system within the confines of a closed area of network Hospitals.
Rapid Rx becomes the first organization to implement these solutions on a large scale basis at the point of care and is seen by eMD as a valued early adopter and strategic alliance partner. Rapid Rx controls in excess of 75,000 patient lives and 300 physicians through its staff model locations in the Southeast.
"eMD`s willingness to present creative solutions relative to pharmaceutical issues and then executing them superbly was mission critical in moving them from vendor to alliance partner to the exclusion of all similar technology entities," explained David C. Bellin, chairman and CEO of Rapid Rx.
"This new alliance with Rapid Rx represents an exciting opportunity for us, one which will provide significant growth for eMD," said Sharon Allred, Executive Vice President. "We appreciate the confidence that Rapid Rx has placed in our product and our staff. We will do everything possible to exceed their expectations."
eMD`s password-protected medication management and charting application includes: electronic prescribing; online medical charting; drug fulfillment to the patient`s pharmacy of choice; and a host of clinical care services such as monitoring chronic disease patients for prescription compliance. Safe Harbor/Forward-looking Statements
Statements in this news release that are not historical are forward- looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in any forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the company, including areas such as: developing technologies; dependence on collaborative partners; the inherent complexity and uncertainty regarding the development of products; early-stage development of BioShield and eMD the result of research and development efforts; future capital needs; uncertainty of additional funding; government regulations; and other factors which are detailed in the company`s periodic reports and registration statements filed with the Securities and Exchange Commission. BioShield does not undertake to revise or update any forward-looking statement to reflect events or circumstances that may arise after the date hereof.
5
Procter & Gamble to Use eMD.com`s Medication Management Solution In Compliance Study Among Ulcerative Colitis Patients
ATLANTA, Sept. 18 /PRNewswire/ -- eMD.com, a business-to-business e-healthcare subsidiary of BioShield Technologies, Inc. (NASDAQ: BSTI), today announced an agreement to conduct a compliance study for Procter & Gamble Pharmaceuticals. The study examines compliance issues among patients suffering from ulcerative colitis.
The six-month study focuses on patients under remission therapy for mild to moderate ulcerative colitis, which afflicts 500,000 people in the United States. P&G expects the research to help it identify and better understand factors influencing medication compliance and/or non-compliance among patients who are prescribed Asacol(R) (mesalamine), the leading drug in the treatment of ulcerative colitis. eMD.com will install its Internet-based medication management solution in the offices of participating gastroenterologists across the U.S.
"As with most drugs, improving patient understanding and compliance is the name of the game," said Mark A. Collar, vice president of P&G`s global pharmaceutical business. "eMD.com`s system gives us an innovative way to do that."
Under the direction of Kevin F. Smith, M.D., M.P.H., Chief Medical Officer, eMD.com`s Clinical Services staff will contact more than 600 patients across the U.S. The research methodology includes utilizing eMD`s state-of-the-art compliance call center coupled with specific disease state education by eMD.com`s healthcare professionals. Results of the study will aggregate all findings to best determine overall compliance issues and trends. The final report will not include confidential or individualized patient information of any kind. "We`re very pleased to partner with a recognized leader like Procter & Gamble on this compliance and education program," said Dr. Smith. "As a business-to-business e-healthcare company focused on improving chronic disease management, we are uniquely positioned to help the industry better understand issues that contribute to appropriate medication compliance and to put forth solutions to improve this critically important area."
This press release contains forward-looking information regarding BioShield Technologies, Inc. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements as to industry trends, future economic performance, anticipated profitability, anticipated revenues and expenses, anticipated transactions and closing dates for such transactions, planned product development, and products or service line growth may be significantly impacted by certain risks and uncertainties, including, but not limited to, failure of the industry to develop at anticipated rates, failure of the Companies` products and services and planned products and services to be timely developed or to gain significant market acceptance, competition and other economic factors. In addition, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue," or the negative other variations thereof or compatible terminology are intended to identify forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Companies disclaim any intention of obligation to update these forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the Companies, including areas such as: the early-stage development of BioShield; the result of research and development efforts; future capital needs; uncertainty of additional funding; and government regulations. Additional risks and uncertainties are described in public filings of BioShield with the Securities and Exchange Commission.